インヒビターの有無にかかわらず、血友病Aの成人および青年におけるMim8を調査する研究

基本情報

NCT ID

NCT05053139

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

281

治験依頼者名

Novo Nordisk A/S

概要

This study is investigating how Mim8 works compared to other medicines in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). When and how often participants will receive Mim8 is dependent on their previous treatment - but is otherwise decided by chance. Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month. The study will last 54-124 weeks (12-29 months) depending on how long participants will be followed in run-in before they start treatment and if they continue in the follow period or transfer to an open label extension study. Participants will have 12-17 clinic visits.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)